Abstract
To the Editor: Apremilast is an oral phosphodiesterase-4 inhibitor that is approved for the treatment of psoriasis.1 It was shown to be effective in controlling progression of vitiligo,2 but another study found that apremilast does not bring any additional benefit to narrowband ultraviolet B light (NB-UVB) phototherapy.3 That study, however, included a low proportion of skin phototypes (SPTs) IV to VI and lacked the advantage of a bilateral comparison study design. Our study evaluated the efficacy of apremilast plus NB-UVB phototherapy compared with NB-UVB phototherapy alone in patients with SPTs IV to VI with generalized vitiligo (≥20% body surface area).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call